摘要
对1例52岁的女性原发性中枢神经系统淋巴瘤患者给予利妥昔单抗联合大剂量甲氨蝶呤(8 g/m^(2))和地塞米松方案治疗。为避免患者在使用大剂量甲氨蝶呤治疗时发生严重不良反应,治疗过程中采取了一系列的检查、血药浓度监测和支持治疗等措施,以保证患者用药安全。
A 52-year old female patient with primary central nervous system lymphoma was treated with rituximab plus high-dose methotrexate(8 g/m2)and dexamethasone.A series of tests of organ functions,monitoring of methotrexate concentration in blood and some supportive cares were carried out to avoid severe adverse events when such a high dose of methotrexate was administered and to ensure safe medication.
作者
王振华
袁燕
吴婷
朱萍
吴蓓倩
WANG Zhenhua;YUAN Yan;WU Ting;ZHU Ping;WU Beiqian(Department of Hematology,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处
《上海医药》
CAS
2021年第15期3-4,64,共3页
Shanghai Medical & Pharmaceutical Journal